There are no guarantees on Wall Street, especially when it comes to dividends. The board of directors of each company decides on the dividend in private.
FRANKLIN LAKES, N.J. , July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics.
FRANKLIN LAKES, N.J. , July 22, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on September 30, 2025 to holders of record on September 8, 2025.
14 Dividend Kings continue to outperform the S&P 500 in 2025. Dividend growth remains healthy, with one recent increase and a collective 2025 growth rate of 5.23%. Seventeen Dividend Kings currently appear undervalued with strong long-term return potential, using Dividend Yield Theory for valuation.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Waters Corporation (NYSE: WAT) and Becton, Dickinson and Company's (NYSE: BDX) Biosciences & Diagnostic Solutions business. Upon completion of the proposed transaction, existing Waters shareholde...
Waters Corp (NYSE:WAT) shares fell more than 12% after it announced a business combination deal with BD Biosciences & Diagnostic Solutions (NYSE:BDX), forming a new life sciences and diagnostics leader focused on high-volume, regulated testing markets. The transaction, structured as a Reverse Morris Trust and valued at approximately $17.5 billion, is expected to significantly expand Waters' mar...
Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 billion of the proceeds to buy back stock.
Strong strategic fit that increases presence in multiple high-growth adjacencies and offers immediate commercial impact from Waters' proven execution model Doubles Waters' total addressable market to approximately $40 billion, with 5-7% annual growth Creates a combined company with pro forma expected 2025 sales of approximately $6.5 billion and adjusted EBITDA of approximately $2.0 billion Incr...
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.